Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Unlocking New Hope: Advances in the Application of Mesenchymal Stromal Cells in Female Infertility.

Created on 07 Jul 2026

Authors

Xinyue Zhou, Yuzi Li, Yixiao Tian, Yanan Guo, Haofei Shen, Tielan Feng, Liyan Wang, Xuehong Zhang

Published in

Current stem cell research & therapy. Jul 03, 2026. Epub Jul 03, 2026.

Abstract

Mesenchymal stromal cell (MSC) therapy represents a rapidly evolving domain within regenerative medicine research and its clinical applications. As a therapeutic approach in regenerative medicine, MSCs therapy holds a distinct position in addressing female infertility, attributed to its low immunogenicity and robust capacities for self-renewal and differentiation. Empirical studies have demonstrated that the transplantation of MSCs derived from various sources, such as menstrual fluid, endometrium, bone marrow, adipose tissue, and umbilical cord, can effectively facilitate the restoration of ovarian and endometrial morphology and function. This offers promising prospects for the treatment of a range of female infertility-related conditions, including ovarian insufficiency, intrauterine adhesion, and polycystic ovary syndrome. This review article examines the underlying mechanisms and recent advancements in research on MSCs from diverse sources within the female reproductive system. Furthermore, it elucidates the application of MSCs in clinical trials targeting ovarian and endometrial pathologies.

PMID:
42411081
Bibliographic data and abstract were imported from PubMed on 07 Jul 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 1
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement